{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:31:08Z","timestamp":1794673868794,"version":"4.9.1"},"reference-count":63,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000295","name":"Epilepsy Research UK","doi-asserted-by":"publisher","award":["P1201"],"award-info":[{"award-number":["P1201"]}],"id":[{"id":"10.13039\/501100000295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","award":["Vera Down 2013 and Margaret Temple 2017"],"award-info":[{"award-number":["Vera Down 2013 and Margaret Temple 2017"]}],"id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104079\/Z\/14\/Z"],"award-info":[{"award-number":["104079\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Autoimmune encephalitis defines brain inflammation caused by a misdirected immune response against self-antigens expressed in the central nervous system. It comprises a heterogeneous group of disorders that are at least as common as infectious causes of encephalitis. The rapid and ongoing expansion of this field has been driven by the identification of several pathogenic autoantibodies that cause polysymptomatic neurological and neuropsychiatric diseases. These conditions often show highly distinctive cognitive, seizure and movement disorder phenotypes, making them clinically recognisable. Their early identification and treatment improve patient outcomes, and may aid rapid diagnosis of an underlying associated tumour. Here we summarise the well-known autoantibody-mediated encephalitis syndromes with neuronal cell-surface antigens. We focus on practical aspects of their diagnosis and treatment, offer our clinical experiences of managing such cases and highlight more basic neuroimmunological advances that will inform their future diagnosis and treatments.<\/jats:p>","DOI":"10.1136\/practneurol-2020-002567","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:23:13Z","timestamp":1623248593000},"page":"412-423","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":201,"title":["Autoimmune encephalitis: clinical spectrum and management"],"prefix":"10.1136","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-6522","authenticated-orcid":false,"given":"Christopher E","family":"Uy","sequence":"first","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5998","authenticated-orcid":false,"given":"Sophie","family":"Binks","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9748","authenticated-orcid":false,"given":"Sarosh R","family":"Irani","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"2025090410130219000_21.5.412.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712"},{"key":"2025090410130219000_21.5.412.2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2025090410130219000_21.5.412.3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00415-019-09590-9","article-title":"The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis","volume":"268","author":"Ramanathan","year":"2021","journal-title":"J Neurol"},{"key":"2025090410130219000_21.5.412.4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2017.04.046","article-title":"Autoantibody-mediated diseases of the CNS: structure, dysfunction and therapy","volume":"132","author":"Varley","year":"2018","journal-title":"Neuropharmacology"},{"key":"2025090410130219000_21.5.412.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir1038"},{"key":"2025090410130219000_21.5.412.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25131"},{"key":"2025090410130219000_21.5.412.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70222-X"},{"key":"2025090410130219000_21.5.412.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2025090410130219000_21.5.412.9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.049676"},{"key":"2025090410130219000_21.5.412.10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S2215-0366(19)30001-X","article-title":"The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data","volume":"6","author":"Al-Diwani","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2025090410130219000_21.5.412.11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ana.25908","article-title":"Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"88","author":"Varley","year":"2020","journal-title":"Ann Neurol"},{"key":"2025090410130219000_21.5.412.12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx070"},{"key":"2025090410130219000_21.5.412.13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52760"},{"key":"2025090410130219000_21.5.412.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt212"},{"key":"2025090410130219000_21.5.412.15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22307"},{"key":"2025090410130219000_21.5.412.16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24979"},{"key":"2025090410130219000_21.5.412.17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025090410130219000_21.5.412.18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"2025090410130219000_21.5.412.19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025090410130219000_21.5.412.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70299-0"},{"key":"2025090410130219000_21.5.412.21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA\n                receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70324-2"},{"key":"2025090410130219000_21.5.412.23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jnnp-2020-325011","article-title":"Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies","volume":"92","author":"McGinty","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090410130219000_21.5.412.24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ana.26013","article-title":"Antibodies contributing to focal epilepsy signs and symptoms score","volume":"89","author":"de Bruijn","year":"2021","journal-title":"Ann Neurol"},{"key":"2025090410130219000_21.5.412.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318584"},{"key":"2025090410130219000_21.5.412.26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25999"},{"key":"2025090410130219000_21.5.412.27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","article-title":"Dppx potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu142"},{"key":"2025090410130219000_21.5.412.29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/WNL.0b013e31825f0522","article-title":"Immunotherapy-Responsive chorea as the presenting feature of LGI1-antibody encephalitis","volume":"79","author":"Tofaris","year":"2012","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002917"},{"key":"2025090410130219000_21.5.412.31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003887"},{"key":"2025090410130219000_21.5.412.32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ane.13207","article-title":"Response to immunotherapy in anti-IgLON5 disease: a systematic review","volume":"141","author":"Cabezudo-Garc\u00eda","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"2025090410130219000_21.5.412.33","first-page":"1149","article-title":"Anti-Lgi1 encephalitis: clinical sydrome and long-term follow-up","volume":"87","author":"Van","year":"2016","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.34","doi-asserted-by":"crossref","unstructured":"Valencia-Sanchez C , Pittock SJ , Mead-Harvey C , et al . Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun 2021:fcaa233. doi:10.1093\/braincomms\/fcaa233","DOI":"10.1093\/braincomms\/fcaa233"},{"key":"2025090410130219000_21.5.412.35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/NDT.S195706","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review","volume":"15","author":"Wang","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025090410130219000_21.5.412.36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10072-014-2022-z","article-title":"Risk of neuroleptic malignant syndrome in patients with NMDAR encephalitis","volume":"36","author":"Caroff","year":"2015","journal-title":"Neurol Sci"},{"key":"2025090410130219000_21.5.412.37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000280"},{"key":"2025090410130219000_21.5.412.38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pediatrneurol.2016.03.023","article-title":"Anti-N-Methyl-D-Aspartate receptor encephalitis: a potential mimic of neuroleptic malignant syndrome","volume":"63","author":"Rozier","year":"2016","journal-title":"Pediatr Neurol"},{"key":"2025090410130219000_21.5.412.39","doi-asserted-by":"crossref","unstructured":"Shin H-R , Jang Y , Shin Y-W , et al . High-Dose diazepam controls severe dyskinesia in anti-NMDA receptor encephalitis. Neurology 2020:10.1212\/CPJ.0000000000001001. doi:10.1212\/CPJ.0000000000001001","DOI":"10.1212\/CPJ.0000000000001001"},{"key":"2025090410130219000_21.5.412.40","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx323"},{"key":"2025090410130219000_21.5.412.41","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.seizure.2021.02.010","article-title":"Long-Term seizure outcome and antiseizure medication use in autoimmune encephalitis","volume":"86","author":"Ilyas-Feldmann","year":"2021","journal-title":"Seizure"},{"key":"2025090410130219000_21.5.412.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"2025090410130219000_21.5.412.44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006783"},{"key":"2025090410130219000_21.5.412.45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.25173","article-title":"N-Methyl-D-Aspartate receptor antibody production from germinal center reactions: therapeutic implications","volume":"83","author":"Makuch","year":"2018","journal-title":"Ann Neurol"},{"key":"2025090410130219000_21.5.412.46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25655"},{"key":"2025090410130219000_21.5.412.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1313-z"},{"key":"2025090410130219000_21.5.412.48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-Dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"key":"2025090410130219000_21.5.412.49","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/brain\/awy109","article-title":"Distinct HLA associations of LGI1 and CASPR2-antibody diseases","volume":"141","author":"Binks","year":"2018","journal-title":"Brain"},{"key":"2025090410130219000_21.5.412.50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ana.25666","article-title":"Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability","volume":"87","author":"Kornau","year":"2020","journal-title":"Ann Neurol"},{"key":"2025090410130219000_21.5.412.51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww208"},{"key":"2025090410130219000_21.5.412.52","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312601"},{"key":"2025090410130219000_21.5.412.53","doi-asserted-by":"crossref","first-page":"10.1212\/WNL.0000000000007096","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000404"},{"key":"2025090410130219000_21.5.412.55","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23577"},{"key":"2025090410130219000_21.5.412.56","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70224-2"},{"key":"2025090410130219000_21.5.412.57","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003009"},{"key":"2025090410130219000_21.5.412.58","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00415-018-9153-8","article-title":"Patient characteristics and outcome associations in AMPA receptor encephalitis","volume":"266","author":"Laurido-Soto","year":"2019","journal-title":"J Neurol"},{"key":"2025090410130219000_21.5.412.59","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"2025090410130219000_21.5.412.60","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000677"},{"key":"2025090410130219000_21.5.412.61","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1212\/WNL.0000000000002775","article-title":"Human neurexin-3\u03b1 antibodies associate with encephalitis and alter synapse development","volume":"86","author":"Gresa-Arribas","year":"2016","journal-title":"Neurology"},{"key":"2025090410130219000_21.5.412.62","doi-asserted-by":"crossref","first-page":"175628561772234","DOI":"10.1177\/1756285617722347","article-title":"Treatment strategies for autoimmune encephalitis","volume":"11","author":"Shin","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"2025090410130219000_21.5.412.63","unstructured":"Joint Formulary Committee . British National Formulary (online). London BMJ Gr.Pharm. Press."}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2020-002567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:13:14Z","timestamp":1757005994000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2020-002567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,17]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/practneurol-2020-002567"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2020-002567","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}